This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Caplacizumab parenteral

Updated 2 Feb 2023 | Parenteral anticoagulants


Injections of caplacizumab.

These products have been produced by recombinant technology using E.coli.

Drugs List

  • CABLIVI 10mg powder + solvent for solution for injection vial
  • caplacizumab 10mg powder + solvent for solution for injection vial
  • Therapeutic Indications


    Acquired thrombotic thrombocytopenic purpura

    Acquired thrombotic thrombocytopenic purpura (aTTP) in conjunction with plasma exchange and immunosuppression.



    Initial dose
    10mg given as a intravenous injection prior to plasma exchange.

    Subsequent doses
    10mg given as subcutaneous injection after each daily plasma exchange for the duration of plasma exchange treatment. Continue the same dosing regimen for 30 days after stopping daily plasma exchange.

    Unresolved immunological disease
    Continue daily subcutaneous administration of 10mg of caplacizumab until resolved.


    Children aged 12 to 18 years
    Weight 40kg or above: (See Dosage; Adult)

    Additional Dosage Information

    After proper training in the subcutaneous injection technique, patients or caregivers may inject the product.

    Missed doses
    Within 12 hours
    Administer missed dose.
    Over 12 hours
    Do not administer missed dose, resume scheduled dosing regime.


    Avoid injection around the navel area. Consecutive injection should not be administered in the same abdominal quadrant.


    Children under 12 years
    Weight below 40kg

    Precautions and Warnings

    Severe hepatic impairment

    Treatment to be initiated and supervised by a specialist
    Monitoring advised in bleeding disorders
    Discontinue at least 7 days prior to scheduled surgery
    Suspend treatment if bleeding requiring medical treatment occurs
    Advise patient to inform physician/dentist of their use of this medication

    Initiation or continuation of treatment with oral anticoagulants or high dose heparin requires a benefit/risk assessment and close monitoring.

    Concomitant treatment with anti-platelet agents and/or low molecular weight heparin (LMWH) requires a benefit/risk assessment and close monitoring.

    Consider the use of von Willebrand factor concentrate to correct haemostasis if significant bleeding occurs or if surgery is required.

    Pregnancy and Lactation


    Caplacizumab is contraindicated during pregnancy.

    The manufacturer recommends that caplacizumab should be avoided during pregnancy. Animal studies did not indicate any signs of toxicity. At the time of writing there is limited published information regarding the use of caplacizumab during pregnancy. Potential risks are unknown.


    Caplacizumab is contraindicated during breastfeeding.

    The manufacturer recommends that a decision should be made whether to discontinue the treatment or breastfeeding, taking into account the benefits of breastfeeding and the therapy. The presence of caplacizumab in human breast milk is unknown but due to its large molecular weight, transfer is not expected. A risk to the child cannot be excluded.

    Side Effects

    Abdominal wall haematoma
    Cerebral infarct
    Erythema at injection site
    Gingival bleeding
    Haemorrhage (injection site)
    Haemorrhoidal haemorrhage
    Injection site reactions
    Ocular haemorrhage
    Rectal haemorrhage
    Subarachnoid haemorrhage
    Upper gastro-intestinal haemorrhage
    Vaginal haemorrhage


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: October 2019

    Reference Sources

    Summary of Product Characteristics: Cablivi 10mg powder and solvent for solution for injection. Sanofi Genzyme. Revised June 2020.

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Caplacizumab. Last revised: 14 October 2019
    Last accessed: 28 February 2019

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.